ClinicalTrials.gg
CompletedNCT02473965Updated Mar 30, 2020Results posted

Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

A Phase 2 interventional study of IGIV-C and Placebo in Myasthenia Gravis, sponsored by Grifols Therapeutics LLC. Completed at 39 sites in 10 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-03-30.

Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.

Enrollment
53rd of 108
60 · median 56
Started
2015
with 3 others
Phase 2
26 of 144
5 open now
Registered
23rd of 144
by date

Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 53rd largest by enrollment of the 108 interventional ones that give a count, is one of 4 that started in 2015, is one of 26 in phase 2, and was the 23rd registered.

Myasthenia Gravis

330 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Myasthenia Gravis with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) as a corticosteroid (CS)-sparing agent in subjects with CS-dependent Myasthenia Gravis (MG).

Read the detailed description

This study consists of 2 phases: IGIV-C Run-in Phase and Corticosteroid Tapering/IGIV-C Maintenance Phase.

In the Run-in Phase, subjects will receive a total of 3 doses of IGIV-C (1 loading dose of 2 g/kg and 2 maintenance doses of 1 g/kg) while maintaining a stable dose of corticosteroids.

In the CS Tapering/IGIV-C Maintenance Phase, subjects will continue 1 g/kg IGIV-C and begin a prescribed CS tapering regimen where the CS dose is decreased every 3 weeks.

Approximately 60 subjects are planned to be enrolled in the study across multiple centers in North America and Europe. The total duration of study participation for each subject is up to 45 weeks.

03

Conditions studied

  • Myasthenia Gravis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Anti-acetylcholine receptor antibody positive
  • Confirmed diagnosis of generalized MG historically meeting the clinical criteria for diagnosis of MG defined by the Myasthenia Gravis Foundation of America (MGFA) classification of Class II, III, IV, or V historically
  • At Screening, subjects may have symptoms controlled by CS or were MGFA Class II-IVa inclusive (Class IVb and Class V excluded). Subjects who only have a history of ocular MG may not enroll.
  • On systemic CS for a minimum period of at least 3 months and on a stable CS dose of >=15 mg/day and \<=60 mg/day (prednisone equivalent) for the month prior to Screening.
  • Had a tapering CS dose that the study investigator considered to be appropriate.
  • At least 1 previous completed attempt to taper CS in order to minimize CS dose (lowest feasible dose based on observed MG signs and symptoms)

Exclusion criteria

Exclusion Criteria:

  • Any dose change in concomitant therapy, other than CS, in the prior 6 months
  • Any change in CS dose or acetylcholinesterase inhibitor (e.g., pyridostigmine) dose in the 1 month prior to Screening
  • A 3-point change in Quantitative Myasthenia Gravis score, increased or decreased, between the Screening/Week -3 (Visit 0) and Baseline (Week 0 [Visit 1])
  • Any episode of myasthenic crisis (MC) in the 1 month prior to Screening, or (at any time in the past) MC or hospitalization for MG exacerbation associated with a previous CS taper attempt
  • Evidence of within the past 5 years (non-melanoma skin cancer, carcinoma in situ of cervix is allowed) or thymoma potentially requiring surgical intervention during the course of the trial (intent to perform thymectomy)
  • Thymectomy within the preceding 6 months prior to Screening
  • Rituximab, belimumab, eculizumab or any monoclonal antibody used for immunomodulation within the past 12 months prior to Screening
  • Have received immune globulin treatment given by IV, subcutaneous, or intramuscular route within the last 3 months prior to Screening
  • Received plasma exchange performed within the last 3 months prior to Screening
  • History of anaphylactic reactions or severe reactions to any blood-derived product
  • History of recent (within the last year) myocardial infarction or stroke
  • Uncontrolled congestive heart failure; embolism; or historically documented (within the last year) changes indicative of myocardial ischemia or atrial fibrillation
  • Current known hyperviscosity or hypercoagulable state
  • Currently receiving anti-coagulation therapy. Oral anti- agents are allowed (e.g., aspirin, clopidogrel, ticlopidine)
  • Females of who are pregnant, have a positive serum pregnancy test, breastfeeding, or are unwilling to practice a highly effective method of throughout the study.
  • Renal impairment
  • or alanine aminotransferase levels exceeding more than 2.5 times the for the expected normal range for the testing laboratory.
  • (Hb) levels \<9 g/dL
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    IGIV-C

    An IGIV-C loading dose of 2 g/kg and maintenance dose of 1 g/kg will be administered in CS dependent subjects with MG.

    Drug: IGIV-C

  • Placebo comparator
    Placebo

    0.9% sodium chloride injection, USP or equivalent

    Drug: Placebo

Interventions

  • DrugIGIV-C

    Run-Phase: 1 loading dose of 2 g/kg IGIV-C and 2 maintenance doses of 1 g/kg IGIV-C Corticosteroid Tapering/IGIV-C Maintenance Phase: 1 g/kg IGIV-C every 3 weeks for up to 36 weeks

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Percent of Subjects Achieving a 50% or Greater Reduction in CS Dose (Prednisone or Equivalent) From Baseline to Week 39

    The average daily CS dose was derived for each subject at each scheduled visit based on the prescribed dose and the time interval taking into account any prescribed dose changes between routinely scheduled visits. Subjects who discontinued the study early with adverse outcomes related to MG were considered as not achieving a 50% or greater reduction. The missing dose reduction at Week 39 was imputed using the worst observation carried forward (WOCF) method. For subjects who did not have CS dose prescribed at Week 39 due to other reasons, the last observation carried forward (LOCF) method was used to impute the prescribed CS dose at Week 39. Baseline was defined as the last non-missing measurement taken prior to first dose of study medication. The percent of subjects achieving ≥50% reduction in CS dose from baseline to Week 39 is presented for each treatment group overall and for the baseline daily prednisone equivalent dose level stratification categories.

    Time frame: Baseline/Week 0 (Visit 1) and Week 39 (Visit 14).

Secondary outcomes

  1. Mean Percent Change in Daily CS Dose (Prednisone or Equivalent) From Baseline to Week 39

    The average daily CS dose was derived for each subject at each scheduled visit based on the prescribed dose and the time interval taking into account any prescribed dose changes between routinely scheduled visits. For subjects who discontinued the study early with adverse outcomes related to MG, the missing dose reduction at Week 39 was imputed using the WOCF method. For subjects who had missing CS dose reduction at Week 39 due to other reasons, the missing CS dose was imputed using the LOCF method. Baseline was defined as the last non-missing measurement taken prior to first dose of study medication. The least squares (LS) mean percent change from baseline in daily CS dose to Week 39 is presented for each treatment group.

    Time frame: Baseline/Week 0 (Visit 1) and Week 39 (Visit 14).

  2. Median Time to First Episode of MG Worsening

    The time to the first episode of MG worsening was defined as the time between baseline and the first instance of QMG total score increase by ≥4 points relative to Baseline/Week 0. The QMG total score is the sum of all 13 items and ranges from 0 to 39. Higher values represent greater severity of illness. If one or more items were missing at a given assessment, the total score was set to missing. The median time to MG worsening was calculated based on Kaplan-Meier methodology. Baseline was defined as the last non-missing measurement taken prior to the first dose of study medication.

    Time frame: From Baseline/Week 0 (Visit 1) to Week 39 (Visit 14).

07

Results

Posted Feb 26, 2020

Participant flow

Sixty subjects with a confirmed diagnosis of generalized myasthenia gravis (MG) historically meeting the clinical criteria for MG diagnosis Class II, III, IV or V of the Myasthenia Gravis Foundation of America were randomized. The study was conducted in 8 countries from November 2015 to February 2019.

Participant flow — Overall Study
MilestoneIGIV-CPlacebo
Started3030
Completed1820
Not completed1210
Withdrew: Adverse event64
Withdrew: Mg worsening41
Withdrew: Withdrawal by subject23
Withdrew: Physician decision02

Outcome measures

PrimaryPercent of Subjects Achieving a 50% or Greater Reduction in CS Dose (Prednisone or Equivalent) From Baseline to Week 39

The average daily CS dose was derived for each subject at each scheduled visit based on the prescribed dose and the time interval taking into account any prescribed dose changes between routinely scheduled visits. Subjects who discontinued the study early with adverse outcomes related to MG were considered as not achieving a 50% or greater reduction. The missing dose reduction at Week 39 was imputed using the worst observation carried forward (WOCF) method. For subjects who did not have CS dose prescribed at Week 39 due to other reasons, the last observation carried forward (LOCF) method was used to impute the prescribed CS dose at Week 39. Baseline was defined as the last non-missing measurement taken prior to first dose of study medication. The percent of subjects achieving ≥50% reduction in CS dose from baseline to Week 39 is presented for each treatment group overall and for the baseline daily prednisone equivalent dose level stratification categories.

Time frame:
Baseline/Week 0 (Visit 1) and Week 39 (Visit 14).
Reported as:
Number · percentage of subjects
Percent of Subjects Achieving a 50% or Greater Reduction in CS Dose (Prednisone or Equivalent) From Baseline to Week 39
percentage of subjectsIGIV-CPlacebo
All subjects60.063.3
15 mg to 40 mg/day58.660.7
41 mg to 60 mg/day100.0100.0
Statistical analysis
  • IGIV-C vs Placebo · Fisher Exact · p = =1.00 (The statistical inference was tested as 2-sided with alpha=0.05.) · Odds ratio (or): 0.868 · 95% CI 0.270 to 2.787
SecondaryMean Percent Change in Daily CS Dose (Prednisone or Equivalent) From Baseline to Week 39

The average daily CS dose was derived for each subject at each scheduled visit based on the prescribed dose and the time interval taking into account any prescribed dose changes between routinely scheduled visits. For subjects who discontinued the study early with adverse outcomes related to MG, the missing dose reduction at Week 39 was imputed using the WOCF method. For subjects who had missing CS dose reduction at Week 39 due to other reasons, the missing CS dose was imputed using the LOCF method. Baseline was defined as the last non-missing measurement taken prior to first dose of study medication. The least squares (LS) mean percent change from baseline in daily CS dose to Week 39 is presented for each treatment group.

Time frame:
Baseline/Week 0 (Visit 1) and Week 39 (Visit 14).
Reported as:
Least squares mean · percent change
Mean Percent Change in Daily CS Dose (Prednisone or Equivalent) From Baseline to Week 39
percent changeIGIV-CPlacebo
Mean Percent Change in Daily CS Dose (Prednisone or Equivalent) From Baseline to Week 39-52.57 ± 8.835-54.15 ± 8.835
Statistical analysis
  • IGIV-C vs Placebo · ANCOVA · p = =0.900 · Ls mean difference: 1.58 · 95% CI -23.52 to 26.68
SecondaryMedian Time to First Episode of MG Worsening

The time to the first episode of MG worsening was defined as the time between baseline and the first instance of QMG total score increase by ≥4 points relative to Baseline/Week 0. The QMG total score is the sum of all 13 items and ranges from 0 to 39. Higher values represent greater severity of illness. If one or more items were missing at a given assessment, the total score was set to missing. The median time to MG worsening was calculated based on Kaplan-Meier methodology. Baseline was defined as the last non-missing measurement taken prior to the first dose of study medication.

Time frame:
From Baseline/Week 0 (Visit 1) to Week 39 (Visit 14).
Reported as:
Median · weeks
Median Time to First Episode of MG Worsening
weeksIGIV-CPlacebo
Median Time to First Episode of MG WorseningNA (33.10 to NA)NA (30.10 to NA)

Adverse events

Collected over Treatment emergent adverse events (TEAEs) were collected from Baseline/Week 0 to Week 39 (approximately 9 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IGIV-C1/30 (3.3%)4/30 (13.3%)21/30 (70%)
Placebo2/30 (6.7%)6/30 (20%)24/30 (80%)
Most frequent serious events
Most frequent serious events
EventIGIV-CPlacebo
Myasthenia gravisNervous system disorders4/301/30
Myasthenia gravis crisisNervous system disorders1/302/30
Renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/301/30
PneumoniaInfections and infestations0/301/30
SepsisInfections and infestations0/301/30
Subcutaneous abscessInfections and infestations0/301/30
Pneumonia staphylococcalInfections and infestations0/301/30
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/301/30
Cardiac arrestCardiac disorders0/301/30
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/301/30
Most frequent other events
Showing 10 of 30
Most frequent other events
EventIGIV-CPlacebo
HeadacheNervous system disorders10/303/30
Myasthenia gravisNervous system disorders7/302/30
Upper respiratory tract infectionInfections and infestations6/303/30
ArthralgiaMusculoskeletal and connective tissue disorders4/306/30
NauseaGastrointestinal disorders5/301/30
NasopharyngitisInfections and infestations2/305/30
Back painMusculoskeletal and connective tissue disorders0/305/30
CoughRespiratory, thoracic and mediastinal disorders3/302/30
UrticariaSkin and subcutaneous tissue disorders3/300/30
Oedema peripheralGeneral disorders2/303/30

Baseline characteristics

The modified intent-to-treat (mITT) population included all randomized subjects who received at least 1 dose of study medication. Subjects were classified according to randomized treatment.

Age, Continuous
Age, Continuous(years)IGIV-CPlaceboTotal Title
Mean47.6 ± 16.9948.5 ± 14.5148.1 ± 15.67
Sex: Female, Male
Sex: Female, Male(Participants)IGIV-CPlaceboTotal Title
Female161834
Male141226
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IGIV-CPlaceboTotal Title
Hispanic or Latino022
Not Hispanic or Latino302858
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IGIV-CPlaceboTotal Title
American Indian or Alaska Native000
Asian325
Native Hawaiian or Other Pacific Islander000
Black or African American011
White272754
More than one race000
Unknown or Not Reported000
Baseline Daily Prednisone Equivalent Dose Level Stratification Categories
Baseline Daily Prednisone Equivalent Dose Level Stratification Categories(Participants)IGIV-CPlaceboTotal Title
15 mg to 40 mg/day292857
41 to 60 mg/day123
Baseline QMG Total Score
Baseline QMG Total Score(units on a scale)IGIV-CPlaceboTotal Title
Mean12.1 ± 6.9811.2 ± 6.4811.6 ± 6.69
08

Study locations

39 sites
  • University of California-Irvine
    Orange, California 92868, United States
  • Yale University School of Medicine, Department of Neurology
    New Haven, Connecticut 06510, United States
  • University of Florida at Shands Jacksonville
    Jacksonville, Florida 32209, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Georgia Regents University
    Augusta, Georgia 30912, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • University of Kansas Medical Center Research Institute, Inc.
    Kansas City, Kansas 66160, United States
  • Rutgers New Jersey Medical School
    Newark, New Jersey 07103, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Ohio State University Wexner Medical Center, Neurology Department
    Columbus, Ohio 43220, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Houston Methodist Neurological Institute
    Houston, Texas 77030, United States
  • University of Vermont Medical Center
    Burlington, Vermont 05405, United States
  • University of Washington Medical Center
    Seattle, Washington 98105, United States
  • UZ Leuven
    Leuven, 3000, Belgium
  • London Health Sciences Centre- University Hospital
    London, Ontario N6A 5A5, Canada
  • University Health Network (UHN) - Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Fakultni nemocnice Brno, Dept of Neurologicka klinika
    Brno, 625 00, Czechia
  • Fakultni nemocnice Ostrava
    Ostrava - Poruba, 708 52, Czechia
  • Vseobecna fakultni nemocnice v Praze, Dept of Neurologicka klinika
    Praha 2, 128 21, Czechia
  • East Tallinn Central Hospital
    Tallinn, 10138, Estonia
  • CHU Strasbourg - Nouvel Hôpital Civil, Clinique Neurologique
    Strasbourg cedex, Bas Rhin 67091, France
  • CHU de Toulouse - Hôpital Purpan, Service de Neurologie Générale
    Toulouse cedex 9, Haute Garonne 31059, France
  • Universitaetsklinikum Regensburg, Parent
    Regensburg, Bayern 93053, Germany
  • Universitaetsklinikum Giessen und Marburg GmbH Standort Marburg
    Marburg, Hessen 35043, Germany
  • Universitaetsmedizin Goettingen, Parent
    Göttingen, Niedersachsen 37075, Germany
  • Krankenhaus Martha-Maria Halle-Doelau, Klinik fuer Neurologie
    Halle, Sachsen Anhalt 6120, Germany
  • Fachkrankenhaus Hubertusburg gGmbH, Klinik f. Neurologie
    Wermsdorf, Sachsen 4779, Germany
  • Universitaetsklinikum Jena, Klinik fuer Neurologie
    Jena, Thueringen 7747, Germany
  • Charité Universitaetsmedizin Berlin, Klinik für Neurologie
    Berlin, 10117, Germany
  • Universitaetsklinikum Hamburg-Eppendorf, Klinik und Poliklinik
    Hamburg, 20246, Germany
  • Jahn Ferenc Del-pesti Korhaz es Rendelointezet, Neurologiai Osztaly
    Budapest, 1204, Hungary
  • Pest Megyei Flor Ferenc Korhaz, Neurologia es Stroke Osztaly
    Kistarcsa, 2143, Hungary
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
    Szeged, 6725, Hungary
  • Hospital of Lithuanian University of Health Sciences Kaunas Clinics
    Kaunas, 50161, Lithuania
  • Uniwersyteckie Centrum Kliniczne, Dept of Neurology
    Gdansk, 80-952, Poland
  • Krakowska Akademia Neurologii Sp z o.o. Centrum Neurologii Klinicznej
    Krakow, 31-505, Poland
  • III Szpital Miejski w Lodzi im. Dr K. Jonschera
    Lodz, 93-113, Poland
  • Samodzielny Publiczny Centralny Szpital Kliniczny
    Warszawa, 02-097, Poland
09

References and documents

Publications

  • Bril V, Szczudlik A, Vaitkus A, Rozsa C, Kostera-Pruszczyk A, Hon P, Bednarik J, Tyblova M, Kohler W, Toomsoo T, Nowak RJ, Mozaffar T, Freimer ML, Nicolle MW, Magnus T, Pulley MT, Rivner M, Dimachkie MM, Distad BJ, Pascuzzi RM, Babiar D, Lin J, Querolt Coll M, Griffin R, Mondou E. Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis. Neurology. 2023 Feb 14;100(7):e671-e682. doi: 10.1212/WNL.0000000000201501. Epub 2022 Oct 21. Erratum In: Neurology. 2023 Sep 12;101(11):501. doi: 10.1212/WNL.0000000000207433. PubMed 36270895 ↗
  • Dalakas MC, Meisel A. Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis. Expert Rev Neurother. 2022 Apr;22(4):313-318. doi: 10.1080/14737175.2022.2057223. Epub 2022 Apr 5. PubMed 35350948 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2015, a primary completion of Feb 2019 and a completion of Feb 2019. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2015
First posted
Jun 17, 2015
Start
Jun 2015
Primary completionActual
Feb 2019
CompletionActual
Feb 2019
Results first posted
Feb 26, 2020
Last update
Mar 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02473965
Responsible party
Sponsor
First posted
Jun 17, 2015
Start date
Jun 2015
Primary completion
Feb 2019
Completion
Feb 2019
Results posted
Feb 26, 2020
Last update
Mar 30, 2020
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion